Black checkmark with a sparkle and a curved line underneath on a white background.
Company

CYPHERPUNK TECHNOLOGIES INC.

Ticker
CYPH
Sector
Industry
Report date
November 16, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Recent news highlights Cypherpunk's financial gains from its Zcash treasury and progress in Phase 3 clinical plans for sirexatamab, alongside broader biotech sector activity.

Recent developments:
  • Cypherpunk reported a swing to Q2 profit driven by gains from its Zcash treasury and advanced Phase 3 plans for sirexatamab, contributing to stock gains [N2].
  • The company is recognized among biotech gainers alongside asset deals and pipeline growth in related companies [N2].
  • Industry coverage highlights Cypherpunk as a cryptocurrency worth consideration relative to AI stocks, reflecting market interest in its digital asset strategy [N1].
Overview

Cypherpunk Technologies Inc. is a Delaware-based company listed on the Nasdaq Capital Market under the ticker CYPH. The company operates in two primary sectors: digital asset management, including cryptocurrency holdings such as Zcash, and biotechnology, focusing on the development and commercialization of therapeutic candidates like sirexatamab (DKN-01). The company maintains a strong liquidity position with substantial cash and current assets relative to liabilities. It is classified as a smaller reporting company and has a significant number of shares outstanding. Cypherpunk's business model integrates digital asset treasury management with biotech clinical development programs, reflecting a diversified operational approach [S1][S2][N2].

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Cypherpunk Technologies Inc. reported net income of $306.005 million and basic EPS of $1.44 for the quarter ended September 30, 2026, with strong liquidity ratios indicating robust financial health. The company operates in both digital asset management and biotechnology sectors, including development of sirexatamab (DKN-01). Recent news highlights include Zcash treasury gains and advancement in biotech clinical plans [S2][N2].

Scenarios for CYPH

Bull case model:

The company's strong liquidity and net income position as of September 2026 support operational flexibility. Advances in the Phase 3 clinical development of sirexatamab and gains from its digital asset treasury, including Zcash holdings, contribute to potential value creation. The diversified business model spanning digital assets and biotechnology may provide multiple avenues for growth and capital appreciation [N2][S2].

Bear case model:

Risks include the inherent volatility and regulatory uncertainty associated with digital asset holdings, which could impact financial results. The biotechnology segment faces typical clinical development risks such as trial outcomes, regulatory approvals, and market acceptance. Additionally, the company's smaller reporting status may limit access to capital markets compared to larger peers. These factors could constrain operational execution and financial performance [S1].

Moat:

Cypherpunk's moat derives from its dual focus on digital asset treasury management and biotechnology development. The company's significant holdings in cryptocurrencies such as Zcash provide a unique financial asset base that can generate gains independent of traditional biotech revenue streams. Concurrently, its biotechnology pipeline, including the development of sirexatamab, offers potential for value creation through clinical advancements. This combination of digital asset exposure and biotech innovation creates a differentiated business model that may be less correlated with typical industry cycles [S1][N2].

Risks overview
Risks summary
The primary risks for Cypherpunk Technologies Inc. stem from digital asset price volatility and regulatory uncertainties, alongside the inherent clinical and regulatory risks in its biotechnology development programs.
Risks details:

• Digital Asset Volatility and Regulatory Risk: The company's financial results are exposed to the highly volatile nature of cryptocurrency prices and evolving regulatory frameworks that could adversely affect the value and liquidity of its digital asset holdings.
• Biotechnology Clinical and Regulatory Risks: Clinical development of sirexatamab and other programs involves uncertainties including trial outcomes, regulatory approvals, and market acceptance, which could impact future revenues and profitability.
• Capital and Market Access Constraints: As a smaller reporting company, Cypherpunk may face challenges in accessing capital markets and scaling operations compared to larger competitors.

FINAL FORECAST FOR CYPH

Final take one line
Cypherpunk Technologies Inc. exhibits very high visibility with detailed SEC disclosures and active engagement in digital assets and biotechnology sectors.
Final take 12 to 24 month view

Business trends: Integration of digital asset treasury management with biotechnology clinical development, including Zcash holdings and sirexatamab advancement.
Execution milestones: Progression of Phase 3 clinical trials for sirexatamab and realization of gains from cryptocurrency treasury.
Key risks: Volatility and regulatory uncertainty in digital assets, clinical and regulatory risks in biotech development, and capital access constraints due to smaller reporting status.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • Cypherpunk Technologies Inc. is a Delaware corporation headquartered in Cambridge, MA, trading on Nasdaq Capital Market under ticker CYPH [S1].
  • As of September 30, 2026, the company reported cash and cash equivalents of $55.988 million and current assets of $526.442 million against current liabilities of $2.385 million, resulting in a very strong current ratio of 220.73 and cash ratio of 23.48 [S2].
  • The company reported net income of $306.005 million and basic earnings per share of $1.44 for the quarter ended September 30, 2026 [S2].
  • Cypherpunk holds a digital asset treasury strategy including holdings in cryptocurrencies such as Zcash, which contributes to its financial results [N2].
  • The company is engaged in biotechnology operations, including development and commercialization of sirexatamab (DKN-01) and other programs [S1].
  • Recent news highlights Cypherpunk's involvement in biotech and cryptocurrency sectors, with mentions of Zcash treasury gains and advancement of Phase 3 sirexatamab plans [N2].
  • The company has a history of private placements and equity incentive plans as disclosed in SEC filings [S1].
  • Cypherpunk is classified as a smaller reporting company and is not a shell company [S1].
  • The aggregate market value of non-affiliate common stock was approximately $12.1 million as of June 30, 2025, with approximately 89.98 million shares outstanding as of March 11, 2026 [S1].
  • The company faces risks related to the volatile nature of digital asset prices, regulatory conditions, and clinical development uncertainties in biotechnology [S1].
Sources
Sources - Context summary

Generated 2026-11-16

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-16 | 10-K
  • S2 | 2026-11-16 | 10-Q
Sources - News headlines
  • N1 | 2026-09-21 | www.nasdaq.com | 2 Cryptocurrencies Worth Buying Over AI Stocks Right Now | https://www.nasdaq.com/articles/2-cryptocurrencies-worth-buying-over-ai-stocks-right-now
  • N2 | 2026-09-03 | www.nasdaq.com | Biotech Gainers: BTAI Asset Deal, BIAF CyPath Growth, CYPH Zcash, GRI Pipeline Drive Gains | https://www.nasdaq.com/articles/biotech-gainers-btai-asset-deal-biaf-cypath-growth-cyph-zcash-gri-pipeline-drive-gains
  • N3 | 2025-08-14 | www.nasdaq.com | Leap Therapeutics Slashes R&D Spending | https://www.nasdaq.com/articles/leap-therapeutics-slashes-rd-spending
  • N4 | 2025-05-13 | www.nasdaq.com | Leap Therapeutics, Inc. (LPTX) Q1 Loss Beats Estimates | https://www.nasdaq.com/articles/leap-therapeutics-inc-lptx-q1-loss-beats-estimates
  • N5 | 2025-03-26 | www.nasdaq.com | LEAP THERAPEUTICS Earnings Results: $LPTX Reports Quarterly Earnings | https://www.nasdaq.com/articles/leap-therapeutics-earnings-results-lptx-reports-quarterly-earnings
  • N6 | 2025-03-26 | www.nasdaq.com | Leap Therapeutics Reports Positive DeFianCe Phase 2 Data Of Sirexatamab In Colorectal Cancer | https://www.nasdaq.com/articles/leap-therapeutics-reports-positive-defiance-phase-2-data-sirexatamab-colorectal-cancer
  • N7 | 2025-03-15 | www.nasdaq.com | LEAP THERAPEUTICS Earnings Preview: Recent $LPTX Insider Trading, Hedge Fund Activity, and More | https://www.nasdaq.com/articles/leap-therapeutics-earnings-preview-recent-lptx-insider-trading-hedge-fund-activity-and
  • N8 | 2025-01-28 | www.nasdaq.com | Leap Therapeutics Plummets On Disappointing DisTinGuish Study Results In Gastric Cancer | https://www.nasdaq.com/articles/leap-therapeutics-plummets-disappointing-distinguish-study-results-gastric-cancer
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine